All News
COVAD2 data:
⬆️proportion of SLE pts from lmHDI countries were on CS(73% vs 59% p=0.0002), antimalarials(81% vs 68% p=0.0002) & IS(66% vs 53%p=0.0009) vs pts from hvhHDI countries
Comorbids more in younger pts from lmHDI (prob from CS use)
#ACR23 ABST2269 @RheumNow @rheumarhyme https://t.co/4CLGFYG1d0
sheila ( View Tweet)
What's the long-term mainentance game plan in IgG4-RD?
WInS IgG4-RD study
China, n=146
IgG4-RD stable disease >12mo
Withdrawing both IM+GC completely has much higher relapse rates vs at least keeping some IM
IgG4-RD needs some steroid-sparing Rx ongoing
#ACR23 L16 @RheumNow https://t.co/1JJpQmFTF5
David Liew drdavidliew ( View Tweet)
L18 @ #ACR23
⭐️Clinical Implications in Primary Sjögren's Syndrome (pSS) by Molecular classification of Salivary Glands (SGs)
➡️ transcriptomic profiling of SGs in Chinese cohort
👉 396 pSS, 87 non-pSS, & 44 early-pSS
➡️ 3 distinct sub-types:
⭐️Pacui-immune/C1… https://t.co/3ZdrghCB6F https://t.co/hZ9S3hvCzv
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Withdrawing immunosuppression and steroids in IgG4-RD
Maintaining immunosuppression with or without steroids associated with low relapse rate
52% of pts who withdrew steroids +immunosuppression relapsed
@RheumNow #ACR23 Abs#L16 https://t.co/xJyDiCkMVD
Robert B Chao, MD ( View Tweet)
L17 #ACR23 @RheumNow
Afimetoran TLR7/8 inhib for cutaneous lupus
Safety: No SAEs, mild-mod AEs, lower than PBO
Nasopharyngitis & bronchitis
Trough concentration consistent from D8 to 113, support 30 mg qd
CLASI change; MCDI 50% Afim v 0% PB, CLASI-50 Afim 50% v 0%
Inhib of IFNGS https://t.co/cKYY6rmIWE
Eric Dein ( View Tweet)
#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
Dr. Rachel Tate ( View Tweet)
L19 #ACR23 @RheumNow
Hunter: TLC599 injxn for knee OA
Liposomal formulation of dexamathasone sodium phosphate
Improved WOMAC Pain, Fxn, and Aver Daily Pain
Separation of ADP at wk 12 through wk 24
2nd injxn at wk 24 - further benefit
@AusRheum https://t.co/PP7lEsclIc
Eric Dein ( View Tweet)
L19 @ #ACR23
⭐️Is sustained relief of OA pain in knee possible with an intraarticular injection?
⭐️TLC599 = liposomal formulation of dexamethasone sodium phosphate (DSP) that can be injected locally
➡️ phase III study assessing efficacy + safety of TLC599 in single or repeat… https://t.co/mQtuhKI52j https://t.co/reswM09VCl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Spencer-Green et al. IA TLC599 (liposomal dexamethasone) in knee OA. Injection baseline and week 24. Both assoc improved symptoms. As always, look at that placebo injection response! Abstr#L19 #ACR23 @RheumNow https://t.co/oYtkYVboKu https://t.co/RweDRdSieQ
Richard Conway ( View Tweet)
Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease
146 pts - 3 Grps
1: withdraw GC+IM 2:withdraw GC but maintain IM; 3: maintain GC+IM
The maintenance of IMs, with or without low-dose GC, superior to withdraw
#ACR23 @rheumnow #abstL16
Bella Mehta bella_mehta ( View Tweet)
L17 @ #ACR23
New therapy on horizon for cutaneous LE (CLE)?
⭐️AFIMETORAN
➡️ TLR7/8 inhibitor
➡️1st-in-class orally bioavailable, potent
⭐️Phase Ib trial
➡️Criteria:
👉18-65 yo SLE vs biopsy proven CLE
👉CLE Dz Area & Severity Index (CLASI-A) at least 6
👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Late-Breaking Abstr#L19 IA steroid can help osteoarthritis knee pain but effect & duration are variable. Phase 3 RCT: improvement in ADP & WOMAC pain favouring TLC5999 (liposomal modification of DEX) vs PBO at all timepoints inc. after repeated injection @RheumNow #ACRBest https://t.co/xUhoFHPExr
Md Yuzaiful Md Yusof ( View Tweet)
Would intraarticular steroids for knee OA be better with a sustained release formulation?
ph3, TLL599 (liposomal delivery dexamethasone) vs normal dex vs placebo
some gains over normal dex
well tolerated
New options always welcome in OA!
@ProfDavidHunter #ACR23 L19 @RheumNow https://t.co/TUrhppHMiD
David Liew drdavidliew ( View Tweet)
L20 #ACR23 @RheumNow
Telitacept - Recomb Fusion targets BlyS, APRIL in RA w inadeq MTX response
ACR 20 60% v 27% PBO (p<0.001), ACR 50 21% v 6% PBO (p<0.001)
DAS28-ESR <3.2 15% v 5%, reduct -1.6 v -1.0
Better PROs, less jt damage prog at w24
Safety SAE 6.4 v 6.7%, no ifn signal https://t.co/PsA6AxUHVW
Eric Dein ( View Tweet)
Sustained relief for knee OA
TLC599 - liposomal formulation of dexamethasone sodium phosphate
Single injection provided relief for 24 weeks, repeat injection with benefit up to wk 52
@RheumNow #ACR23 Abs#L19
#ACRBest https://t.co/BNGb3nHw8C
Robert B Chao, MD ( View Tweet)
#ACR23 Late-Breaking Abstr#L20 Phase 3 RCT in China: Telitacicept (BAFF-APRIL-i) in MTX-IR #RA met ACR20 response vs PBO.
+ve: less radiographic damage
-ve: lower rate ACR50 (21%), homogenous population, no H2H active comparator
Unclear its place in current Mx @RheumNow https://t.co/SAc4B1aRD1
Md Yuzaiful Md Yusof ( View Tweet)
Telitacicept (BlyS/APRIL inhibitor) ph3 in RA
wholly in China, after SLE approval there (SLE trial now w global sites)
Efficacy okay, no better than other b/tsDMARDs
What's the hook here, in a crowded RA market incl biosimilars?
Safety does look good though
#ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A
David Liew drdavidliew ( View Tweet)
ICYMI
Interesting study by Dr LWGarcia et al:
👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN
👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares
#ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT
sheila ( View Tweet)
Interesting late breaker!
Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression
No difference in safety profile compared to placebo
@RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
Robert B Chao, MD ( View Tweet)
Telitacicept (BlyS/APRIL inhibitor) in MTX-IR RA. Phase 3 RCT. 479 patients. ACR20 60.0% vs 26.9%. ACR50 21.4% vs. 5.9%. Radiographic benefit also. Safety looks ok. Abstr#L20 #ACR23 #ACRbest @RheumNow https://t.co/qcinGeRX2d https://t.co/SIKKW7xhwV
Richard Conway ( View Tweet)